Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

BACKGROUND Fluoroquinolones are now recommended for the treatment of respiratory tract infections due to Streptococcus pneumoniae, particularly when the isolates are resistant to beta-lactam antibiotics. Although pneumococci with reduced susceptibility to fluoroquinolones have been identified, their prevalence has not been determined in a defined population. METHODS We performed susceptibility testing on 7551 isolates of S. pneumoniae obtained from surveillance in Canada in 1988 and from 1993 to 1998. Pneumococci with reduced susceptibility to fluoroquinolones (defined as a minimal inhibitory concentration of ciprofloxacin of at least 4 microg per milliliter) were further characterized. We also examined antibiotic prescriptions dispensed in Canadian retail pharmacies. RESULTS Between 1988 and 1997, fluoroquinolone prescriptions increased from 0.8 to 5.5 per 100 persons per year. The prevalence of pneumococci with reduced susceptibility to fluoroquinolones increased from 0 percent in 1993 to 1.7 percent in 1997 and 1998 (P=0.01). Among adults, the prevalence increased from 1.5 percent in 1993 and 1994 combined to 2.9 percent in 1997 and 1998 combined. The prevalence was higher in isolates from older patients (2.6 percent among those 65 years of age or older vs. 1.0 percent among those 15 to 64 years of age, P<0.001) and among those from Ontario (1.5 percent, vs. 0.4 percent among those from the rest of Canada; P< 0.001). Fluoroquinolone use was greatest among the elderly and in Ontario. The 75 isolates (17 serotypes) of pneumococci with reduced susceptibility to fluoroquinolones were submitted by 40 laboratories in eight provinces. Reduced susceptibility to fluoroquinolones was associated with resistance to penicillin. CONCLUSIONS The prevalence of pneumococci with reduced susceptibility to fluoroquinolones is increasing in Canada, probably as a result of selective pressure from the increased use of fluoroquinolones.

[1]  F. Tenover,et al.  Emergence of drug-resistant pneumococcal infections in the United States. , 1994, JAMA.

[2]  J. Kellner,et al.  Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice. , 1998, Canadian family physician Medecin de famille canadien.

[3]  F. Goldstein,et al.  Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992–93 Western Europe and USA collaborative surveillance study , 1996 .

[4]  A. Marchese,et al.  Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. , 1995, The Journal of antimicrobial chemotherapy.

[5]  L. Peterson,et al.  Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis , 1991, Antimicrobial Agents and Chemotherapy.

[6]  M. Cetron,et al.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. , 1996, The Journal of infectious diseases.

[7]  F. Tenover,et al.  In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits. , 1996, The Journal of antimicrobial chemotherapy.

[8]  G. Doern,et al.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study , 1996, Antimicrobial agents and chemotherapy.

[9]  R. Wise,et al.  Streptococcus pneumoniae resistance to fluoroquinolones , 1996, The Lancet.

[10]  A. Anzueto,et al.  Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. Campbell,et al.  Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia. , 1999, Chest.

[12]  L. Hall,et al.  Application of molecular typing to the epidemiology of Streptococcus pneumoniae. , 1998, Journal of clinical pathology.

[13]  J Stephenson,et al.  Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. , 1996, JAMA.

[14]  J. Kahn,et al.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. , 1997, Diagnostic microbiology and infectious disease.

[15]  L. Gutmann,et al.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA , 1996, Antimicrobial agents and chemotherapy.

[16]  M. Pfaller,et al.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  A. Tomasz,et al.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. , 1991, The Journal of infectious diseases.

[18]  R. Wise,et al.  The activity of grepafloxacin against respiratory pathogens in the UK. , 1997, The Journal of antimicrobial chemotherapy.

[19]  B. Spratt,et al.  Multiply antibiotic-resistant Streptococcus pneumoniae recovered from Spanish hospitals (1988-1994): novel major clones of serotypes 14, 19F and 15F. , 1996, Microbiology.

[20]  W. Snodgrass,et al.  Potential role of fluoroquinolones in pediatric infections. , 1989, Reviews of infectious diseases.

[21]  Jerome J. Schentag,et al.  Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. , 1997, Diagnostic microbiology and infectious disease.

[22]  J. Bartlett,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Community-Acquired Pneumonia in Adults: Guidelines for Management , 1998 .

[23]  J. Hedrick,et al.  High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. , 1995, The Pediatric Infectious Disease Journal.

[24]  R N Grüneberg,et al.  Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. , 1996, Diagnostic microbiology and infectious disease.

[25]  J. Ambler,et al.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae , 1996, Antimicrobial agents and chemotherapy.

[26]  L. Setchanova.  Clinical isolates and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Hospital for Infectious Diseases, Sofia, Bulgaria, 1991-1993. , 1995, Microbial drug resistance.

[27]  J. Duval,et al.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro , 1996, Antimicrobial agents and chemotherapy.

[28]  A. Barry,et al.  Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin. , 1997, The Journal of antimicrobial chemotherapy.

[29]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[30]  D. Low,et al.  Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network , 1996, Antimicrobial agents and chemotherapy.

[31]  B. Cookson,et al.  Reports on surveillance of antimicrobial resistance in individual countries. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Domagala,et al.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Kaku,et al.  Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan , 1995, Antimicrobial agents and chemotherapy.

[34]  J. Moore,et al.  Pneumococcal resistance in the UK. , 1997, The Journal of antimicrobial chemotherapy.

[35]  T. Klaukka,et al.  Resistance to erythromycin in group A streptococci. , 1992, The New England journal of medicine.

[36]  D. Hooper.  Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  G. Stefánsdóttir,et al.  Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study , 1996, BMJ.

[38]  M. Hjálmarsdóttir,et al.  Increasing penicillin resistance in pneumococci in Iceland , 1992, The Lancet.

[39]  D. Hooper.  Expanding Uses of Fluoroquinolones: Opportunities and Challenges , 1998, Annals of Internal Medicine.

[40]  A. Tomasz,et al.  Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. , 1993, The Journal of infectious diseases.

[41]  R. Muñoz,et al.  ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype , 1996, Antimicrobial agents and chemotherapy.

[42]  G. Weinstock,et al.  Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites , 1990, Journal of clinical microbiology.

[43]  R. Marre,et al.  Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of , 1998, The Journal of antimicrobial chemotherapy.

[44]  J. Ambler,et al.  Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. , 1998, The Journal of antimicrobial chemotherapy.

[45]  M. Reichler,et al.  Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia. , 1995, The Journal of infectious diseases.

[46]  K. Luey,et al.  Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong , 1995, Antimicrobial agents and chemotherapy.

[47]  J. Spika,et al.  Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[48]  R. Chaisson,et al.  Infectious complications with respiratory pathogens despite ciprofloxacin therapy. , 1991, The New England journal of medicine.

[49]  I. Brook,et al.  Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.